BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, Sors A, Charman WN, Summers RJ, Sexton PM, Christopoulos A, Langmead CJ. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology 2019;144:244-55. [PMID: 30359639 DOI: 10.1016/j.neuropharm.2018.10.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Egyed A, Kiss DJ, Keserű GM. The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs. Front Pharmacol 2022;13:847788. [PMID: 35355719 DOI: 10.3389/fphar.2022.847788] [Reference Citation Analysis]
2 Inoue Y, Uchiyama M, Umeuchi H, Onishi K, Ogo H, Kitajima I, Matsushita I, Nishino I, Uchimura N. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials. BMC Psychiatry 2022;22:141. [PMID: 35193545 DOI: 10.1186/s12888-022-03785-7] [Reference Citation Analysis]
3 Szczepańska K, Podlewska S, Dichiara M, Gentile D, Patamia V, Rosier N, Mönnich D, Ruiz Cantero MC, Karcz T, Łażewska D, Siwek A, Pockes S, Cobos EJ, Marrazzo A, Stark H, Rescifina A, Bojarski AJ, Amata E, Kieć-Kononowicz K. Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties. ACS Chem Neurosci 2022;13:1-15. [PMID: 34908391 DOI: 10.1021/acschemneuro.1c00435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lamb YN. Pitolisant: A Review in Narcolepsy with or without Cataplexy. CNS Drugs 2020;34:207-18. [PMID: 31997137 DOI: 10.1007/s40263-020-00703-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
5 Nirogi R, Grandhi VR, Medapati RB, Ganuga N, Benade V, Gandipudi S, Manoharan A, Abraham R, Jayarajan P, Bhyrapuneni G, Shinde A, Badange RK, Subramanian R, Petlu S, Jasti V. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders. J Psychopharmacol 2021;35:713-29. [PMID: 33546570 DOI: 10.1177/0269881120986418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Trofimiuk E, Wielgat P, Car H. Selective H3 Antagonist (ABT-239) Differentially Modifies Cognitive Function Under the Impact of Restraint Stress. Front Syst Neurosci 2020;14:614810. [PMID: 33603652 DOI: 10.3389/fnsys.2020.614810] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Hino N, Marumo T, Kotani M, Shimazaki T, Kaku-fukumoto A, Hikichi H, Karasawa J, Tomishima Y, Komiyama H, Tatsuda E, Nozawa D, Nakamura T, Chaki S. A Novel Potent and Selective Histamine H 3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, and Wake-Promoting and Procognitive Effects in Rodents. J Pharmacol Exp Ther 2020;375:276-85. [DOI: 10.1124/jpet.120.000185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Park J, Langmead CJ, Riddy DM. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. ACS Pharmacol Transl Sci 2020;3:88-106. [PMID: 32259091 DOI: 10.1021/acsptsci.9b00075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 11.5] [Reference Citation Analysis]
12 Mocking TAM, Buzink MCML, Leurs R, Vischer HF. Bioluminescence Resonance Energy Transfer Based G Protein-Activation Assay to Probe Duration of Antagonism at the Histamine H3 Receptor. Int J Mol Sci 2019;20:E3724. [PMID: 31366084 DOI: 10.3390/ijms20153724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lappano R, Mallet C, Rizzuti B, Grande F, Galli GR, Byrne C, Broutin I, Boudieu L, Eschalier A, Jacquot Y, Maggiolini M. The Peptide ERα17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells. Cells 2019;8:E590. [PMID: 31207943 DOI: 10.3390/cells8060590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
14 Kenakin T. Prescient Indices of Activity: The Application of Functional System Sensitivity to Measurement of Drug Effect. Trends Pharmacol Sci 2019;40:529-39. [PMID: 31109799 DOI: 10.1016/j.tips.2019.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther 2019;200:69-84. [PMID: 31028835 DOI: 10.1016/j.pharmthera.2019.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
16 Reiner D, Stark H. Ligand binding kinetics at histamine H3 receptors by fluorescence-polarization with real-time monitoring. European Journal of Pharmacology 2019;848:112-20. [DOI: 10.1016/j.ejphar.2019.01.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]